A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9?Engineered T Cells (CTX131) in Adult Subjects with Relapsed or Refractory Solid Tumors